Levosimendan Altan

Levosimendan, the active ingredient in Levosimendan Altan, is a calcium sensitizer presented as an intravenous solution for intravenous use. It provides positive inotropic support and vasodilation for patients with acute decompensated heart failure, improving cardiac output during severe episodes.

GNH USA supplies Levosimendan Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for critical care settings. Customers benefit from reliable logistics, temperature‑controlled shipping, and comprehensive documentation to meet import requirements.

Levosimendan acts on the cardiovascular system to enhance contractility in acute heart failure. - Acute decompensated heart failure: Improves cardiac contractility and reduces preload, helping to stabilize hemodynamics.

Levosimendan may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Dizziness: feeling of light‑headedness. - Flushing: warm sensation with skin reddening. - Arrhythmia: occasional irregular heartbeat.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure fall requiring intervention. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced heart muscle blood flow. - Anaphylactic reaction: rare allergic response. - Liver enzyme elevation: abnormal hepatic function tests. - Thrombocytopenia: low platelet count.

Levosimendan requires careful monitoring and specific handling precautions. - Dose titration: Adjust infusion rate based on hemodynamic response. - Hypotension risk: Monitor blood pressure closely during initiation. - Renal impairment: Use with caution in patients with reduced renal function. - Electrolyte disturbances: Check serum potassium and magnesium levels. - Concurrent vasodilators: Avoid excessive vasodilation when combined with other agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan may interact with several cardiovascular agents.

Major Interactions (Avoid): - Concurrent use with other potent vasodilators: may cause severe hypotension. - Combination with beta‑blockers: can blunt the desired inotropic effect. - Use with strong CYP3A4 inhibitors: may increase plasma concentrations.

Moderate Interactions (Monitor Closely): - Co‑administration with diuretics: may enhance electrolyte shifts. - Concurrent use with other inotropes: monitor for additive cardiac effects. - Interaction with nitrates: monitor blood pressure closely.